LRRC31 Inhibitors
LRRC31 inhibitors encompass a diverse array of chemical compounds that influence the activity of LRRC31 through various cellular processes. Proteasome inhibitors such as Bortezomib, MG-132, Lactacystin, and Epoxomicin operate by impeding the proteolytic degradation pathway, which could lead to the accumulation of polyubiquitinated proteins, potentially including LRRC31 or its regulatory factors, thereby reducing its activity. MLN 4924 targets the neddylation process, which, if LRRC31 is subject to neddylation-dependent degradation, could result in the stabilization and subsequent diminishment of LRRC31 function due to the disruption of its normal protein turnover. The inhibitors PI-103, LY 294002, and Wortmannin target the phosphoinositide 3-kinase (PI3K) pathway, a key signaling cascade that, when inhibited, could reduce LRRC31 activity if LRRC31 is regulated by PI3K signaling. Rapamycin, by inhibiting mTOR, may further decrease LRRC31 activity if LRRC31 is modulated by mTOR-dependent pathways.
Additionally, the MAPK pathway, which is essential for various cellular functions, can be interrupted by specific inhibitors such as PD 98059 and U0126, both of which target MEK. This could lead to a decrease in LRRC31 functional activity if LRRC31 is modulated by the MEK/ERK signaling axis. SP600125, a JNK pathway inhibitor, could similarly reduce LRRC31 activity if JNK signaling is involved in the regulation of LRRC31. These compounds collectively represent a spectrum of indirect LRRC31 inhibitors by targeting distinct signaling pathways and post-translational mechanisms that are putatively connected to the regulation of LRRC31 function within the cell. While these inhibitors do not directly interact with LRRC31, their effects on upstream regulatory mechanisms and signaling cascades provide a means to diminish LRRC31 activity, which could be crucial for understanding the protein's role in cellular physiology and potential pathological states.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN 4924 is a NEDD8-activating enzyme inhibitor that prevents neddylation, a process that modifies proteins, including those involved in cell cycle regulation and apoptosis. By inhibiting this enzyme, MLN 4924 indirectly leads to the stabilization of proteins targeted for degradation, which could diminish LRRC31 function if LRRC31 is a substrate for neddylation-dependent degradation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that prevents the degradation of polyubiquitinated proteins, leading to an accumulation of these proteins in the cell. If LRRC31 is regulated by ubiquitin-proteasome-mediated degradation, Bortezomib's action would result in a diminishment of LRRC31 functional activity due to the disruption of its normal turnover. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a peptide aldehyde that inhibits proteasomes, leading to the accumulation of ubiquitinated proteins. This accumulation can indirectly diminish the function of LRRC31 if it relies on the proteasomal pathway for its regulation. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a specific inhibitor of the proteasome that irreversibly binds to its active site. This binding leads to an accumulation of proteins that are normally degraded by the proteasome, potentially diminishing the functional activity of LRRC31 by altering its degradation kinetics. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a potent, selective, and irreversible proteasome inhibitor. By blocking proteasome-mediated degradation, it may lead to the accumulation of proteins including LRRC31 or its regulatory proteins, thereby potentially diminishing LRRC31 activity. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
PI-103 is a dual inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). If LRRC31 function is modulated by signaling pathways involving PI3K/mTOR, inhibition by PI-103 could lead to a reduction in LRRC31 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a specific inhibitor of PI3Ks, which can lead to diminished activation of downstream signaling pathways such as Akt. If LRRC31 is functionally activated by PI3K/Akt signaling, inhibition by LY 294002 would result in diminished LRRC31 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can decrease the activity of mTORC1 and mTORC2 complexes. If LRRC31 is regulated by mTOR signaling, Rapamycin application could indirectly diminish LRRC31 activity by altering downstream signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. By inhibiting PI3K, it could diminish LRRC31 activity if LRRC31's functional state is contingent upon PI3K-mediated signal transduction. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a specific inhibitor of MEK, which is upstream of ERK in the MAPK pathway. If LRRC31 activity is influenced by ERK signaling, the use of PD 98059 would lead to a decrease in LRRC31 activity through this pathway. | ||||||